We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
Cap. Flow
+$254M
Cap. Flow %
266.32%
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99

Top Buys

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.6M
2
BAX icon
Baxter International
BAX
+$3.81M
3
AKBA icon
Akebia Therapeutics
AKBA
+$2.87M
4
OTIC
Otonomy, Inc.
OTIC
+$2.46M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$1.81M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$8.82M
2
CELG
Celgene Corp
CELG
+$6.57M
3
DYAX
DYAX CORPORATION
DYAX
+$6.35M
4
CMG icon
Chipotle Mexican Grill
CMG
+$5.44M
5
VTRS icon
Viatris
VTRS
+$2.57M

Sector Composition

1 Healthcare 48.43%
2 Technology 4.06%
3 Consumer Discretionary 2.5%
4 Consumer Staples 1.74%
5 Materials 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
376
DELISTED
DYAX CORPORATION
DYAX
– –
-168,700
Closed -$6.35M
DYAX
377
PUT
DELISTED
DYAX CORPORATION
DYAX
– –
-222,700
Closed -$31K
HOT
378
CALL
DELISTED
STARWOOD HOTELS & RESORTS WORLDWIDE, INC.
HOT
– –
-9,000
Closed -$2K
HOT
379
DELISTED
STARWOOD HOTELS & RESORTS WORLDWIDE, INC.
HOT
– –
-11,500
Closed -$785K
CELG
380
CALL
DELISTED
Celgene Corp
CELG
– –
-28,800
Closed -$3K
CELG
381
DELISTED
Celgene Corp
CELG
– –
-54,834
Closed -$6.57M
CELG
382
PUT
DELISTED
Celgene Corp
CELG
– –
-55,700
Closed -$567K
DSCI
383
CALL
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-5,500
Closed -$2K
DSCI
384
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-50,817
Closed -$232K
LNKD
385
DELISTED
LinkedIn Corporation
LNKD
– –
-8,577
Closed -$1.26M
LNKD
386
PUT
DELISTED
LinkedIn Corporation
LNKD
– –
-9,100
Closed -$82K
RPTP
387
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-198,100
Closed -$9K
RPTP
388
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-8,568
Closed -$45K
RPTP
389
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-127,400
Closed -$220K
12 13 14 15
16

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q1 2016 Portfolio in Review

As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.

  • FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
  • FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
  • FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
  • FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
  • FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
  • FT Options opened 183 new positions and closed 99 in Q1 2016.
  • FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.

Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.